Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes

This ongoing Phase 2/3 study investigates the pharmacogenomic relationship between specific single nucleotide polymorphisms (SNPs) in estrogen receptor (ER) and UDP-glucuronosyltransferase (UGT) genes and the therapeutic efficacy and safety of Raloxifene in patients with breast cancer lobular carcinoma in situ (BC-LCIS). The study involves 600 participants, randomly assigned to receive either a generic form of Raloxifene hydrochloride or another Raloxifene formulation, both administered at 60 mg daily. The primary endpoints are to identify ER SNP genotypes associated with therapeutic efficacy and UGT SNP genotypes linked to adverse effects. The study employs precise gene sequencing techniques to correlate genetic variations with clinical outcomes. While the study is not yet recruiting, it aims to provide insights into personalized treatment approaches based on genetic profiling. Safety data and adverse event profiles are being closely monitored, although specific statistics and outcomes are not yet available. The study's completion is anticipated by December 2026, with potential implications for tailoring breast cancer treatment based on genetic markers.

This study involves patients with a type of breast condition called LCIS, which can increase the risk of breast cancer. Researchers are examining how Raloxifene, a medication used to treat breast cancer, interacts with specific genes in patients. They are particularly interested in two types of genes: one that may influence how well the drug works and another that may relate to side effects. By analyzing blood samples and breast tissue, the researchers hope to find patterns that could help doctors understand which patients might benefit most from Raloxifene and who might face more risks. This could lead to more personalized treatment plans for breast cancer patients. However, the study is still ongoing, and results will take time to analyze. It's important for patients to know that while this research is promising, it is still in the early stages, and more studies will be needed to confirm the findings.